AUPH - Aurinia Pharmaceuticals Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

AUPH

AURINIA PHARMACEUTICALS INC.

NASDAQ

$16.01

▲ UP 2.04% (0.32)

KEY STATISTICS

Market Cap$2.06 B

52w High$19.25

52w Low$10.90

Dividend Yield—

Frequency—

P/E15.70

Volume682.53K

Shares Out.128.60M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Kevin C. Tang

COMPENSATION 2026

Salary$822,877

Stock Awards$1,965,321

Incentive Plan Pay$864,021

All Other Comp.$13,182

Total$5,858,590

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 3, 2014

METHOD OF GOING PUBLIC

Dual Listing

FULL TIME EMPLOYEES

128

PRICE TARGET

Target High$16.00

Target Low$16.00

Target Median$16.00

Target Consensus$16.00

UPCOMING EARNINGS

DateNov 3, 2026

DayTuesday

Rev. Est.$83.61M

NOV

TUE

SPLIT RECORD

DATE	TYPE	RATIO
2013-11-08	Reverse	1:50
2013-10-23	Reverse	1:50

ETFS HOLDING THIS STOCK

ETFS HOLDING

126

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

38.61%

HOLDERS

374

TOP 8 OF 374 · RANKED BY POSITION SIZE

Tang Capital Management LLC

Goldman Sachs Group Inc

5.6M sh

$95.36M

Nea Management Company, LLC

4.0M sh

$43.87M

Two Sigma Investments, LP

3.5M sh

$58.84M

Arrowstreet Capital, Limited Partnership

PRICE

$16.01 ▲ UP 2.04% (+$0.32)

OVERLAYS

About Aurinia Pharmaceuticals Inc.

https://www.auriniapharma.com ↗

Aurinia Pharmaceuticals Inc. is a Canadian biopharmaceutical company developing and commercializing therapies like LUPKYNIS for unmet medical needs such as lupus nephritis, with collaborations including Otsuka Pharmaceutical.

INDUSTRY

Biotechnology

A PRODUCT AURINIA PHARMACEUTICALS INC. IS KNOWN FOR

LUPKYNIS (voclosporin)

LUPKYNIS (voclosporin) is the first FDA-approved oral treatment for active lupus nephritis, serving as Aurinia's main product and revenue source.

COMPETITORS

COMPETITOR

Aurinia Pharmaceuticals in 2025

SENTIMENT: + POSITIVE

EARNINGS · NOVEMBER 4, 2025

Aurinia Pharmaceuticals Boosts 2025 Sales Guidance Following Strong Q3 Performance and LUPKYNIS Sales Growth

Aurinia Pharmaceuticals announced strong financial results for the third quarter of 2025, beating analyst expectations for both earnings per share and revenue. [7, 9] The company reported a significant 27% increase in net product sales for its flagship drug, LUPKYNIS, which prompted an increase in its full-year 2025 sales guidance to between $265 million and $270 million. [1, 2] This positive announcement highlighted the company's strong commercial execution and growing market penetration for its lupus nephritis treatment.

CAPITAL ALLOCATION · JULY 2025 · IN PROGRESS

Aurinia Pharmaceuticals Doubles Down on Shareholder Returns with $150 Million Share Buyback Expansion

In a significant move to enhance shareholder value, Aurinia Pharmaceuticals' Board of Directors approved a $150 million increase to its existing share repurchase program, bringing the total authorization to $300 million. This decision underscores the company's strong financial position, driven by robust sales of its primary drug, LUPKYNIS, and its commitment to returning capital to investors.